An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Mirion Technologies Appoints Michael Rossi as President of Mirion Medical
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Mirion Technologies has appointed Michael Rossi as the new President of Mirion Medical, reporting directly to CEO Tom Logan. Rossi, with extensive experience from Novartis and other companies, aims to leverage his expertise in nuclear medicine to boost organic and inorganic growth within the company. Logan expressed confidence in Rossi's leadership abilities, highlighting the exciting growth opportunities ahead for Mirion. The company, headquartered in Atlanta, is a leading provider of radiation detection and analysis solutions, employing around 2,800 personnel across 13 countries.
Positive
Appointment of Michael Rossi as President of Mirion Medical could enhance leadership and strategic direction.
Rossi's extensive experience in nuclear medicine may drive growth and margin expansion.
Negative
None.
ATLANTA--(BUSINESS WIRE)--
Mirion Technologies, Inc. (“Mirion,” “we” or the “Company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced the appointment of Michael Rossi as the President of Mirion Medical. Michael will report directly to Mirion’s CEO, Tom Logan, who had been acting as President of the business segment.
Michael joins Mirion from Novartis, where he most recently served as the Head of Radioligand Imaging for the Advanced Accelerator Applications business. Prior to Novartis, Michael spent five years at Jubilant Pharma where he served in several different roles with increasing levels of responsibility. Michael also brings experience from GE Healthcare, Tyco Healthcare/Mallinckrodt and Syncor International to the Mirion team. Michael earned a Bachelor of Science in Pharmacy degree from the University of the Sciences – Philadelphia College of Pharmacy and carries the Authorized Nuclear Pharmacist Certification from Butler University. Michael has also served on several Boards of Directors and remains a Licensed Pharmacist in the state of Pennsylvania.
“I am thrilled to welcome Michael to the Mirion team,” said Tom Logan, Mirion’s CEO. “Michael has a unique blend of domain experience and leadership qualities in the nuclear medicine space. His appointment comes at an exciting time for the Company, as we aim to drive organic and inorganic growth and margin expansion across our medical business. I am confident that Michael will accelerate the attainment of our healthcare ambitions.”
“I am incredibly excited to be joining Mirion Medical at such an impactful time in the Company’s growth trajectory,” added Michael Rossi. “What Tom and the team have built over the last few years is truly impressive and I look forward to building off the solid momentum with my new colleagues.”
About Mirion
Mirion Technologies is a leading provider of detection, measurement, analysis and monitoring solutions to the nuclear, defense, medical and research end markets. The organization aims to harness its unrivaled knowledge of ionizing radiation for the greater good of humanity. Headquartered in Atlanta (GA – USA), Mirion employs around 2,800 people and operates in 13 countries. For more information, and for the latest news and content from Mirion, visit ir.mirion.com.
Michael Rossi has been appointed as the new President of Mirion Medical.
What previous experience does Michael Rossi have?
Michael Rossi previously served as the Head of Radioligand Imaging at Novartis and held various roles at Jubilant Pharma, GE Healthcare, and other companies.
Who does Michael Rossi report to at Mirion?
Michael Rossi reports directly to Tom Logan, the CEO of Mirion Technologies.
What are the growth ambitions of Mirion Technologies?
Mirion Technologies aims to drive organic and inorganic growth along with margin expansion in its medical business.
How many employees does Mirion Technologies have?
Mirion Technologies employs approximately 2,800 people.
